Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit ...

Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter.

Amgen (NASDAQ:AMGN) reported second quarter earnings above expectations for the fourth time in a row, while also posting a ...

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

Amgen narrowed its 2024 adjusted earnings estimate and now expects a profit of $19.10 to $20.10 per share, compared with its previous view of $19.00 to $20.20.

Amgen reported adjusted profit of $1.235 billion, down 2% from $1.265 billion a year prior, and earnings per share of $1.14 a share, up 2% from $1.12 a share a year prior.

Analysts had expected $6.17 per share on revenue of $16.4 billion. Amgen’s shares rose $3.51, or 4.4 percent, to $82.80 after hours, on top of a 1.7 percent gain during regular trading.

(Reuters) -Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to speculate on the impact of U.S. tariffs, tax policy would be a ...

Amgen posted first-quarter net income of $1 billion, or 98 cents a share, compared to net income of $1.1 billion, or $1.01 a share, a year ago. Amgen said its adjusted per-share profit was $1.08.

Amgen shares earlier closed up $1.83, or 1.7 percent, to $111.20 on the Nasdaq, and were down 1.5 percent in after-hours trading.

SAN FRANCISCO (MarketWatch) - Amgen Inc. late Monday said its first-quarter net profit rose 11% over the same period last year, but the biggest biotechnology ...